- Home
- KZIA vs PLX Comparison
KZIA vs PLX Comparison
Compare KZIA & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KZIA | PLX |
|---|---|---|
| Founded | 1994 | 1993 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 186.7M | 182.9M |
| IPO Year | 2002 | 1996 |
Fundamental Metrics
Financial Performance| Metric | KZIA | PLX |
|---|---|---|
| Price | $9.55 | $2.73 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $28.36 | N/A |
| AVG Volume (30 Days) | 286.0K | ★ 701.9K |
| Earning Date | 11-06-2026 | 08-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.27 |
| Revenue | N/A | ★ $52,744,000.00 |
| Revenue This Year | N/A | $55.77 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $10.04 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.86 | $1.60 |
| 52 Week High | $17.40 | $3.19 |
Technical Indicators
Market Signals| Indicator | KZIA | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 37.28 | 55.26 |
| Support Level | $9.01 | $2.59 |
| Resistance Level | $14.85 | $2.75 |
| Average True Range (ATR) | 0.68 | 0.09 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 23.62 | 50.10 |
Price Performance
Historical ComparisonAbout KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.